SciDEX
Main
🏠Dashboard🔬Analyses📈Exchange🏛The Agora🗣Debates🔍Research Gaps⚖Compare
Knowledge
📖Wiki🕸Knowledge Graph🗺Atlas📦Artifacts🧬Protein Designs📄Papers📓Notebooks🔎Search
System
🏛Senate⚔Quests💰Resources🔨Forge💹Economics📊Experiments🤖Agents🚦Status📑Docs
Info
ℹVision⭐Showcase📽Demo
📖

Local Field Potentials of Subthalamic Nucleus in Parkinson's Disease (NCT05820425)

wiki page Created: 2026-04-02 13:40:08 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-clinical-trials-lfp-subthalamic-nuc
Related Entities
clinical-trials-lfp-subthalamic-nucleus-pd-nct05820425
Metadata
slugclinical-trials-lfp-subthalamic-nucleus-pd-nct05820425
entity_typeclinical
kg_node_idNone
🌍 Provenance Graph 1 nodes, 0 edges

No provenance edges found

Linked Artifacts (191)
mentions🧪Bacterial Enzyme-Mediated Dopamine Precursor Synthesis90%
related🧪Bacterial Enzyme-Mediated Dopamine Precursor Synthesis90%
related🧫Cytochrome Therapeutics70%
related🧫Cytochrome Therapeutics70%
related🧫s:** - Single-cell RNA-seq to measure editing efficiency acr60%
related🧫Metabolic Pathway-Targeted Therapy in ALS60%
related🧫ALS Progression Rate Heterogeneity — mechanism and biomarker60%
related🧫ALS Regional Onset and Spread: Network-Level Staging Model60%
related🧫Sporadic ALS Initiation Biology: Deep Phenotyping of At-Risk60%
related🧫Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Tri60%
related🧫Blood Biomarker vs Tau PET for Treatment Monitoring60%
related🧫Brainstem Circuit Modulation for PSP60%
related🧫Mechanism: C9orf72 Hexanucleotide Repeat Expansion in ALS/FT60%
related🧫C9orf72 Phenotype Divergence: ALS vs FTD Mechanism Study60%
related🧫Environmental Exposure Causal Attribution in ALS — Experimen60%
related🧫FXTAS Phenotypic Penetrance: Why Only 40% of FMR1 Premutatio60%
related🧫Microbiome-Gut Barrier Signatures in ALS — Experiment Design60%
related🧫N-of-1 Clinical Trial Design for CBS/PSP60%
related🧫Pre-Symptomatic Tau Detection in MAPT Mutation Carriers60%
related🧫Pre-Symptomatic Detection and Intervention Timing in Genetic60%
related🧫Progranulin Replacement Therapy for FTD — Vector Development60%
related🧫Mechanism: Progranulin Loss and TDP-43 Pathology in FTD60%
related🧫PSP and CBS Biomarker Validation Study60%
related🧫Sleep and Respiratory Network Interaction in ALS — Experimen60%
related🧫TDP-43 PET Ligand Development for FTD and ALS60%
related🧫Viral and Post-Infectious Mechanisms in ALS — Experiment Des60%
related🧫AAV Serotype Comparison for LRRK2 Knockdown in PD Gene Thera60%
related🧫AAV-LRRK2 IND-Enabling Study Design60%
related🧫AAV Serotype Comparison for LRRK2 Knockdown in PD60%
related🧫Alpha-Synuclein SAA Kinetics Study — Biological Staging Back60%
related🧫Alpha-Synuclein Aggregation Triggers — Sporadic PD Initiatio60%
related🧫Computational Modeling of Alpha-Synuclein Propagation in PD60%
related🧫Basic Mechanism: Membrane-Driven Alpha-Synuclein Nucleation60%
related🧫Alpha-Synuclein Seed Amplification Assay Validation60%
related🧫Alpha-Synuclein Spreading Mechanism — Prion-Like Propagation60%
related🧫Antiviral Therapy Trial for Parkinson's Disease60%
related🧫Astrocyte Ferritin Iron Metabolism Dysfunction in Parkinson&60%
related🧫Axonal Transport Dysfunction Validation in Parkinson's 60%
related🧫cGAS-STING Pathway Validation Study in Parkinson's Dise60%
related🧫Chaperone-Mediated Autophagy Dysfunction in PD - Experiment 60%
related🧫Combination Therapy Sequencing in Parkinson's Disease60%
related🧫CRISPR Gene Correction Approaches for CBS/PSP60%
related🧫Alpha-Synuclein Staging and Spreading in DLB — Spatial Propa60%
related🧫DNA Damage Repair Deficiency Validation Study in Parkinson&#60%
related🧫Mechanism: Selective Vulnerability of Dopaminergic Neurons i60%
related🧫Endocannabinoid System Dysfunction Validation in Parkinson&#60%
related🧫Epigenetic Dysregulation Validation in Parkinson's Dise60%
related🧫ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De60%
related🧫Exercise-BDNF-Mitophagy Biomarker Study in PD60%
related🧫Ferroptosis Validation in Parkinson's Disease60%
related🧫GLP-1 Agonist Neuroprotection Mechanism in PD60%
related🧫Glymphatic-Circadian Axis Enhancement Therapy for Parkinson&60%
related🧫Gut-Brain Axis Pathogenesis in Parkinson's Disease — Me60%
related🧫Lipid Droplet-Lysosome Axis Therapeutic Testing in Parkinson60%
related🧫Gene Therapy: AAV Serotype Comparison for LRRK2 Knockdown60%
related🧫AAV-LRRK2 Gene Therapy IND-Enabling Study Design60%
related🧫LRRK2/GBA Mutation Carrier Resilience — Why Some Carriers Ne60%
related🧫Macroautophagy Dysfunction in PD - Experiment Design60%
related🧫Validate Mitochondria-Lysosome Contact Site Dysfunction in P60%
related🧫Validation: Membrane-Nucleation in iPSC Neurons60%
related🧫Metabolic Syndrome-Parkinson's Disease Axis Clinical Tr60%
related🧫Experiment Design: Metal Ion-Synuclein-Mitochondria Axis in 60%
related🧫Gut Microbiome-Derived Metabolites in Alpha-Synuclein Propag60%
related🧫MLCS Quantification in Parkinson's Disease60%
related🧫Experiment: Multi-Ethnic PD GWAS60%
related🧫Multiscale Computational Modeling of Protein Aggregation Kin60%
related🧫Neural Oscillation Dysfunction Validation in Parkinson'60%
related🧫NLRP3 Inflammasome Validation Study in Parkinson's Dise60%
related🧫Non-Dopaminergic Neurotransmitter Degeneration in PD - Exper60%
related🧫Non-Motor Symptom Progression in Parkinson's Disease — 60%
related🧫Oligodendrocyte-Myelin Dysfunction Validation in Parkinson&#60%
related🧫Parkinson's Disease Subtype Classification — Precision 60%
related🧫Peroxisomal Dysfunction Validation in Parkinson's Disea60%
related🧫Peroxisome Dysfunction Validation in Parkinson's Diseas60%
related🧫Prodromal Parkinson's Disease Biomarker Development — E60%
related🧫Proteasome-Ubiquitin System Dysfunction Validation in Parkin60%
related🧫Purinergic Signaling Dysfunction Validation in Parkinson60%
related🧫Regulated Necrosis Validation Study in Parkinson's Dise60%
related🧫Sirtuin Dysfunction Validation in Parkinson's Disease60%
related🧫Sirtuin Pathway Dysfunction Validation in Parkinson's D60%
related🧫Stress Granule Dysfunction Validation in Parkinson's Di60%
related🧫Synaptic Mitochondrial Resilience Enhancement for Parkinson&60%
related🧫Synaptic Vesicle Trafficking Dysfunction Validation in Parki60%
related🧫TREM2 Agonist Therapy for Parkinson's Disease — Experim60%
related🧫s:** - Single-cell RNA-seq to measure editing efficiency acr54%
related🧫Metabolic Pathway-Targeted Therapy in ALS54%
related🧫ALS Progression Rate Heterogeneity — mechanism and biomarker54%
related🧫ALS Regional Onset and Spread: Network-Level Staging Model54%
related🧫Sporadic ALS Initiation Biology: Deep Phenotyping of At-Risk54%
related🧫Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Tri54%
related🧫Blood Biomarker vs Tau PET for Treatment Monitoring54%
related🧫Brainstem Circuit Modulation for PSP54%
related🧫Mechanism: C9orf72 Hexanucleotide Repeat Expansion in ALS/FT54%
related🧫C9orf72 Phenotype Divergence: ALS vs FTD Mechanism Study54%
related🧫Environmental Exposure Causal Attribution in ALS — Experimen54%
related🧫FXTAS Phenotypic Penetrance: Why Only 40% of FMR1 Premutatio54%
related🧫Microbiome-Gut Barrier Signatures in ALS — Experiment Design54%
related🧫N-of-1 Clinical Trial Design for CBS/PSP54%
related🧫Pre-Symptomatic Tau Detection in MAPT Mutation Carriers54%
related🧫Pre-Symptomatic Detection and Intervention Timing in Genetic54%
related🧫Progranulin Replacement Therapy for FTD — Vector Development54%
related🧫Mechanism: Progranulin Loss and TDP-43 Pathology in FTD54%
related🧫PSP and CBS Biomarker Validation Study54%
related🧫Sleep and Respiratory Network Interaction in ALS — Experimen54%
related🧫TDP-43 PET Ligand Development for FTD and ALS54%
related🧫Viral and Post-Infectious Mechanisms in ALS — Experiment Des54%
related🧫AAV Serotype Comparison for LRRK2 Knockdown in PD Gene Thera54%
related🧫AAV-LRRK2 IND-Enabling Study Design54%
related🧫AAV Serotype Comparison for LRRK2 Knockdown in PD54%
related🧫Alpha-Synuclein SAA Kinetics Study — Biological Staging Back54%
related🧫Alpha-Synuclein Aggregation Triggers — Sporadic PD Initiatio54%
related🧫Computational Modeling of Alpha-Synuclein Propagation in PD54%
related🧫Basic Mechanism: Membrane-Driven Alpha-Synuclein Nucleation54%
related🧫Alpha-Synuclein Seed Amplification Assay Validation54%
related🧫Alpha-Synuclein Spreading Mechanism — Prion-Like Propagation54%
related🧫Antiviral Therapy Trial for Parkinson's Disease54%
related🧫Astrocyte Ferritin Iron Metabolism Dysfunction in Parkinson&54%
related🧫Axonal Transport Dysfunction Validation in Parkinson's 54%
related🧫cGAS-STING Pathway Validation Study in Parkinson's Dise54%
related🧫Chaperone-Mediated Autophagy Dysfunction in PD - Experiment 54%
related🧫Combination Therapy Sequencing in Parkinson's Disease54%
related🧫CRISPR Gene Correction Approaches for CBS/PSP54%
related🧫Alpha-Synuclein Staging and Spreading in DLB — Spatial Propa54%
related🧫DNA Damage Repair Deficiency Validation Study in Parkinson&#54%
related🧫Mechanism: Selective Vulnerability of Dopaminergic Neurons i54%
related🧫Endocannabinoid System Dysfunction Validation in Parkinson&#54%
related🧫Epigenetic Dysregulation Validation in Parkinson's Dise54%
related🧫ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De54%
related🧫Exercise-BDNF-Mitophagy Biomarker Study in PD54%
related🧫Ferroptosis Validation in Parkinson's Disease54%
related🧫GLP-1 Agonist Neuroprotection Mechanism in PD54%
related🧫Glymphatic-Circadian Axis Enhancement Therapy for Parkinson&54%
related🧫Gut-Brain Axis Pathogenesis in Parkinson's Disease — Me54%
related🧫Lipid Droplet-Lysosome Axis Therapeutic Testing in Parkinson54%
related🧫Gene Therapy: AAV Serotype Comparison for LRRK2 Knockdown54%
related🧫AAV-LRRK2 Gene Therapy IND-Enabling Study Design54%
related🧫LRRK2/GBA Mutation Carrier Resilience — Why Some Carriers Ne54%
related🧫Macroautophagy Dysfunction in PD - Experiment Design54%
related🧫Validate Mitochondria-Lysosome Contact Site Dysfunction in P54%
related🧫Validation: Membrane-Nucleation in iPSC Neurons54%
related🧫Metabolic Syndrome-Parkinson's Disease Axis Clinical Tr54%
related🧫Experiment Design: Metal Ion-Synuclein-Mitochondria Axis in 54%
related🧫Gut Microbiome-Derived Metabolites in Alpha-Synuclein Propag54%
related🧫MLCS Quantification in Parkinson's Disease54%
related🧫Experiment: Multi-Ethnic PD GWAS54%
related🧫Multiscale Computational Modeling of Protein Aggregation Kin54%
related🧫Neural Oscillation Dysfunction Validation in Parkinson'54%
related🧫NLRP3 Inflammasome Validation Study in Parkinson's Dise54%
related🧫Non-Dopaminergic Neurotransmitter Degeneration in PD - Exper54%
related🧫Non-Motor Symptom Progression in Parkinson's Disease — 54%
related🧫Oligodendrocyte-Myelin Dysfunction Validation in Parkinson&#54%
related🧫Parkinson's Disease Subtype Classification — Precision 54%
related🧫Peroxisomal Dysfunction Validation in Parkinson's Disea54%
related🧫Peroxisome Dysfunction Validation in Parkinson's Diseas54%
related🧫Prodromal Parkinson's Disease Biomarker Development — E54%
related🧫Proteasome-Ubiquitin System Dysfunction Validation in Parkin54%
related🧫Purinergic Signaling Dysfunction Validation in Parkinson54%
related🧫Regulated Necrosis Validation Study in Parkinson's Dise54%
related🧫Sirtuin Dysfunction Validation in Parkinson's Disease54%
related🧫Sirtuin Pathway Dysfunction Validation in Parkinson's D54%
related🧫Stress Granule Dysfunction Validation in Parkinson's Di54%
related🧫Synaptic Mitochondrial Resilience Enhancement for Parkinson&54%
related🧫Synaptic Vesicle Trafficking Dysfunction Validation in Parki54%
related🧫TREM2 Agonist Therapy for Parkinson's Disease — Experim54%
related🔬What are the mechanisms underlying what are the mechanisms b50%
related🔬The disease-associated microglia (DAM) phenotype involves TR50%
related🔬What are the mechanisms underlying what are the mechanisms b50%
related🔬What are the mechanisms underlying what are the mechanisms b50%
related🔬The disease-associated microglia (DAM) phenotype involves TR50%
related🔬Is disrupted sleep a cause or consequence of neurodegenerati50%
related🔬Is disrupted sleep a cause or consequence of neurodegenerati50%
related🔬Comprehensive analysis of immune cell subtypes in neurodegen50%
related🔬What cell types are most vulnerable in Alzheimers Disease ba50%
related🔬What cell types are most vulnerable in Alzheimer's Dise50%
related🔬What are the most promising therapeutic strategies for targe50%
related🔬How to break the GBA-alpha-synuclein bidirectional loop for 50%
related🔬Can gut-brain axis modulation prevent or slow Alzheimer'50%
related🔬Astrocytes adopt A1 (neurotoxic) and A2 (neuroprotective) ph50%
mentions🔬What cell types are most vulnerable in Alzheimers Disease ba40%
mentions🔬What cell types are most vulnerable in Alzheimer's Dise40%
mentions🔬How to break the GBA-alpha-synuclein bidirectional loop for 40%
mentions🔬The disease-associated microglia (DAM) phenotype involves TR40%
mentions🔬The disease-associated microglia (DAM) phenotype involves TR40%
mentions🔬Is disrupted sleep a cause or consequence of neurodegenerati40%
mentions🔬Is disrupted sleep a cause or consequence of neurodegenerati40%
mentions🔬Comprehensive analysis of immune cell subtypes in neurodegen40%
mentions🔬What are the most promising therapeutic strategies for targe40%
mentions🔬Can gut-brain axis modulation prevent or slow Alzheimer'40%
mentions🔬Astrocytes adopt A1 (neurotoxic) and A2 (neuroprotective) ph40%
mentions🔬What are the mechanisms underlying what are the mechanisms b40%
mentions🔬What are the mechanisms underlying what are the mechanisms b40%

💬 Discussion

SciDEX — scidex.ai — Dashboard | Mission Control | Status | How it Works | GitHub